#United States #Stamford #Stamford Health #egnite #Pathway Labs

Transforming Heart Patient Management with AI

In an innovative effort aimed at transforming cardiovascular care, egnite, Inc., in collaboration with Pathway Labs and Stamford Health, has launched a groundbreaking clinical pilot program that deploys an advanced ECG-based AI screening tool. This initiative is designed to significantly improve the identification and management of patients suffering from structural heart issues.

The CardioCare® Platform: Enhancing Patient Care

The pilot leverages egnite's CardioCare® platform along with Pathway Labs’ newly cleared electrocardiogram (ECG) algorithm, known as EchoNext. This cutting-edge tool is capable of analyzing 12-lead ECG waveforms to detect various cardiac conditions, including structural heart disease, heart failure, and pulmonary hypertension. As the first AI tool of its kind cleared for use in the US, EchoNext promises to enhance patient care pathways substantially.

When EchoNext identifies a need for further evaluation with an echocardiogram, the findings are integrated and assessed within the CardioCare platform. It compiles the ECG results with the patient's comprehensive medical history, ensuring that care teams can prioritize follow-up for those patients deemed most at risk. This capability is pivotal in addressing the challenge of effectively managing follow-up treatment for identified patients, a task that can often burden healthcare providers.

Objective and Impact of the Pilot

The initiative's main goal is not just to identify at-risk patients through screening but also to ensure they receive timely and appropriate follow-up. The CardioCare platform has already been adopted across more than 80 heart programs, reflecting its versatility and effectiveness in clinical workflows. As the framework for this pilot program, CardioCare provides real-time analytics which assist clinical teams in navigating from detection to diagnosis—all while maintaining efficient workflows that help alleviate additional strain on medical staff.

Dr. Rahul Sharma, director of structural interventions and a senior medical advisor at egnite, expressed excitement about the program, stating, "AI can identify patients at risk, but the real challenge lies in ensuring they receive correct follow-up evaluation and treatment, all without overburdening busy clinical teams. CardioCare bridges that gap effectively." This pilot seeks to measure critical outcomes including the rates at which echocardiograms are completed and the duration from initial flagging to specialist evaluation.

Collaborators in Innovation

Stamford Health, as a key partner in this initiative, has already reported positive outcomes using the CardioCare platform since 2022, having identified nearly 300 patients with significant heart disease who were previously unmonitored or untreated. Dr. Arzhang Fallahi, the director of structural heart at Stamford Health, highlighted the potential of integrating Pathway Labs' technology, emphasizing its role in enhancing their capability to detect heart diseases more proactively within the tens of thousands of ECGs processed annually.

David Hsi, the chief of cardiology at Stamford Health, added that the introduction of this AI algorithm represents an important expansion of their current cardiac imaging programs with a sharp focus on improving patient care quality.

Concluding Thoughts

Edwards Lifesciences, a leader in structural heart innovation, is contributing funding to the pilot to bolster earlier identification of patients with structural heart conditions, demonstrating a collaborative approach to patient-centered care. egnite's extensive network, which includes over 1,200 cardiovascular facilities, allows for a comprehensive implementation of the AI tool, facilitating an evidence-based approach to patient management.

This pilot program not only aims to validate the efficacy of AI in cardiovascular settings but also seeks to establish a sustainable model for utilizing advanced technology in everyday patient care practices. With its potential to streamline processes and enhance outcomes, the collaboration among egnite, Pathway Labs, and Stamford Health signifies a promising advancement in the field of heart health, ultimately aiming for improved life quality for patients with cardiovascular issues.

As such initiatives continue to evolve, they not only represent a leap forward in technology but also embody the critical need to adapt healthcare delivery to meet the challenges of modern medicine.